The Geneva Association: Life Insurers Should Prepare for Implications of Genetics in Highly Fragmented Regulatory Landscape
The Geneva Association, the leading international think tank of the insurance industry, has released the research paper Genetics and Life Insurance: A view into the microscope of regulation, in which it reviews key aspects of the use of genetic information in life insurance.
The use of genetic information for life, disability, critical illness and long-term care insurance is likely to increase in spite of a highly fragmented regulatory environment. The growing availability of genetic testing at ever lower prices is already giving insureds the option to purchase online “direct-to-consumer” tests. One of the questions raised is whether policyholders should be required to share their genetic information with life insurers.
The paper focuses specifically on the regulatory implications of genetic testing. Ronald Klein, Director of The Geneva Association’s Global Ageing research programme, identified that for life, disability, critical illness and long-term care insurance, regulations on the use of genetic information typically fall into five categories. Therefore, there is a whole spectrum ranging from countries that have no genetic-specific regulatory framework; to countries with a clear-cut prohibition or moratorium on the use of genetic information. Each scenario—including the ones in between—has different consequences.
A crucial implication of widespread use of genetic information in insurance is anti-selection by individuals who discover, after taking a genetic test, that they are pre-disposed to certain medical conditions.
“Voluntary insurance is based upon the principle of pooling of like risks. When a potential policyholder has information about his or her health that is not shared with the insurance company, this could lead to anti-selection where poorer risks purchase more insurance and better risks purchase little or no insurance. An insurer would find it extremely difficult to cover claim payments with existing revenues for pools in which there were many anti-selective risks,” Mr Klein commented.
The asymmetry of information may distort the functioning of insurance markets, as insurers would lack information that would help them better price the risk. The asymmetry would also affect insureds who avoid taking medical or genetic tests due to fear of being denied insurance, which could adversely affect their health.
“Life insurers need to closely monitor trends in genetic science and proactively engage with stakeholders (including regulators, medical professionals, industry groups, and genetic counsellors) to agree reasonable ‘self-regulation’, in order to pre-empt regulation in the future,” said Mr Klein. “This may be a prudent approach to counterbalance unwanted restrictive regulation.”
The Geneva Association
Director of Communications
+41 44 200 4906
+41 44 200 49 96
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Exclusive Group Adds Mellanox to BigTec Portfolio19.10.2017 08:00 | Pressemelding
Exclusive Group, the value-added services and technologies (VAST) group, today announced it has struck a major distribution agreement with Mellanox Technologies to add the market-leading vendor’s datacentre interconnect solutions to the global BigTec portfolio. The deal, which sees Mellanox and BigTec team up in 24 countries across EMEA and APAC, brings global expansion opportunities to both parties as well as hundreds of reseller partners, providing the ideal complement to storage and hyper-converged solutions from fellow BigTec vendors including Nutanix and Rubrik. “Mellanox has a unique and comprehensive technology offering that reflects both its commitment to open standards in networking and cloud computing, and its hunger to continually disrupt the datacentre market,” said Martin Bichler, Group Vendor Manager, BigTec. “This is yet another bonus for BigTec specialist resellers and
More Firms Select Duco for Mandatory MiFID II Reconciliation19.10.2017 07:01 | Pressemelding
Duco, the global provider of self-service data normalization and reconciliation services, today announced that a further three firms will be using Duco Cube, the company’s flagship reconciliation solution, for MiFID II reporting reconciliation. The firms include Redburn, Europe’s largest independent equities broker, and two global banks. Ranith de Silva, Operations Manager at Redburn, said: “MiFID II transaction data needs to undergo a number of enrichment processes between front office capture and the final report, which need to be replicated in the reconciliation process, covering large complex data sets. The quick deployment, flexibility and usability of Duco's self-service application enables us to efficiently build towards this reconciliation process with very little technical support.” Regular reconciliation is a mandatory requirement under MiFID II. The firms w
SIAE MICROELETTRONICA Successfully Tests The SDN Application iVeritas in Telefónica Deutschland’s SDN Live Wireless Network19.10.2017 07:00 | Pressemelding
SIAE MICROELETTRONICA announces the successful deployment of iVeritas in Telefónica Deutschland's mobile backhaul as part of the TST project. Telefónica Deutschland Transport SDN Trial (TST), is a project whose long-term aim is offering value added services on future 5G network infrastructure in an SDN environment. As part of this project SIAE MICROELETTRONICA, a Telefónica long term supplier of wireless technology, deployed its new SDN application named iVeritas offering multivendor performance analytics and preventive maintenance analysis. iVeritas sits on top of the OpenDaylight transport SDN controller that through an SDN mediator interfaces to existing SNMP microwave links, the selected portion of the network was composed by links from three different vendors. iVeritas collected performance information from the links, correlating the data and presenting them acco
Rimini Street Expands Investment and Operations in Europe18.10.2017 22:00 | Pressemelding
Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the appointment of industry leader Marc Chesover as general manager of Europe, the Middle East and Africa (EMEA). The Company also announced the launch of its French subsidiary, hiring of new staff and opening of its new office in Paris, France. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006654/en/ Rimini Street Expands Investment and Operations in Europe (Photo: Business Wire) Enterprise Software Veteran Leads EMEA Operations Rimini Street’s new general manager, Marc Chesover, will lead the Company’s sales and service delivery operations across EMEA, and the next p
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy18.10.2017 21:43 | Pressemelding
Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171018006639/en/ CAR T therapy is a breakthrough in hematologic cancer treatment in which
IFF Launches Re-Imagine…™ Programs to Tap Unmet Consumer Opportunities, Speed Innovation18.10.2017 20:15 | Pressemelding
Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris:IFF), a leading innovator of sensory experiences that move the world, launched their Re-Imagine programs to accelerate innovation and increase agility to capture unmet opportunities in the changing food and beverage market. Based on a combination of future trends analysis, consumer insights, and a modernized cross-category development process, the programs guide the Company’s research and development efforts to ensure an innovation pipeline that addresses evolving consumer needs and desires. “The Re-Imagine programs area tangible expression of our commitment to advance taste for our customers – and consumers,” said IFF Chairman and CEO Andreas Fibig. “It is another way in which we show how we are dedicated to being our customers’ partner of choice as we progress on our business strategy, imbu
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom